yh32364
EGFR Overexpression
Yuhan CorporationPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the EGFR Overexpression cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tgfβr-Ko Car-Egfr T Cells Chinese PLA General Hospital | Phase 1 | CC |
MVF-HER-2 (266-296) Pravin T.P Kaumaya | Phase 1 | CC |
Same molecule, other indications
yh32364 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →